231 related articles for article (PubMed ID: 23291984)
1. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
2. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Ai M; Qiu S; Lu Y; Fan Z
Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
[TBL] [Abstract][Full Text] [Related]
3. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
4. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Weaver AM; Silva CM
Breast Cancer Res; 2007; 9(6):R79. PubMed ID: 17997837
[TBL] [Abstract][Full Text] [Related]
5. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
[TBL] [Abstract][Full Text] [Related]
6. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
7. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Falkenberg N; Anastasov N; Höfig I; Bashkueva K; Lindner K; Höfler H; Rosemann M; Aubele M
Mol Oncol; 2015 Jan; 9(1):282-94. PubMed ID: 25241146
[TBL] [Abstract][Full Text] [Related]
8. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Castro NE; Lange CA
Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
[TBL] [Abstract][Full Text] [Related]
9. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.
Ikeda O; Sekine Y; Mizushima A; Nakasuji M; Miyasaka Y; Yamamoto C; Muromoto R; Nanbo A; Oritani K; Yoshimura A; Matsuda T
J Biol Chem; 2010 Dec; 285(49):38093-103. PubMed ID: 20929863
[TBL] [Abstract][Full Text] [Related]
10. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Shen CH; Chen HY; Lin MS; Li FY; Chang CC; Kuo ML; Settleman J; Chen RH
Cancer Res; 2008 Oct; 68(19):7779-87. PubMed ID: 18829532
[TBL] [Abstract][Full Text] [Related]
11. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
Ludyga N; Anastasov N; Rosemann M; Seiler J; Lohmann N; Braselmann H; Mengele K; Schmitt M; Höfler H; Aubele M
Mol Cancer Res; 2013 Apr; 11(4):381-92. PubMed ID: 23364537
[TBL] [Abstract][Full Text] [Related]
12. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
Regan Anderson TM; Peacock DL; Daniel AR; Hubbard GK; Lofgren KA; Girard BJ; Schörg A; Hoogewijs D; Wenger RH; Seagroves TN; Lange CA
Cancer Res; 2013 Sep; 73(18):5810-20. PubMed ID: 23928995
[TBL] [Abstract][Full Text] [Related]
13. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
[TBL] [Abstract][Full Text] [Related]
14. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE
PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872
[TBL] [Abstract][Full Text] [Related]
15. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
16. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.
Ikeda O; Miyasaka Y; Sekine Y; Mizushima A; Muromoto R; Nanbo A; Yoshimura A; Matsuda T
Biochem Biophys Res Commun; 2009 Jun; 384(1):71-5. PubMed ID: 19393627
[TBL] [Abstract][Full Text] [Related]
17. Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells.
Carpenter RL; Paw I; Dewhirst MW; Lo HW
Oncogene; 2015 Jan; 34(5):546-57. PubMed ID: 24469056
[TBL] [Abstract][Full Text] [Related]
18. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Ikeda O; Mizushima A; Sekine Y; Yamamoto C; Muromoto R; Nanbo A; Oritani K; Yoshimura A; Matsuda T
Cancer Sci; 2011 Apr; 102(4):756-61. PubMed ID: 21205088
[TBL] [Abstract][Full Text] [Related]
19. BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
Miah S; Banks CAS; Ogunbolude Y; Bagu ET; Berg JM; Saraf A; Tettey TT; Hattem G; Dayebgadoh G; Kempf CG; Sardiu M; Napper S; Florens L; Lukong KE; Washburn MP
Sci Adv; 2019 Oct; 5(10):eaaw3113. PubMed ID: 31681835
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
